The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Dabigatran is an innovative anticoagulant, a new generation of thin blood drugs, known as the best drug for prevention of stroke in the past 60 years.
The global Dabigatran market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Dabigatran is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Dabigatran is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Dabigatran in Deep Vein Thrombosis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Dabigatran include Pfizer, Bayer Healthcare, GlaxoSmithKline, Boehringer Ingelheim, Aspen Holdings, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dabigatran, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dabigatran.
Report Scope
The Dabigatran market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dabigatran market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dabigatran companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bayer Healthcare
GlaxoSmithKline
Boehringer Ingelheim
Aspen Holdings
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries
Segment by Type
Tablets
Capsule
Others
Segment by Application
Deep Vein Thrombosis
Pulmonary Embolism
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dabigatran companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Dabigatran is an innovative anticoagulant, a new generation of thin blood drugs, known as the best drug for prevention of stroke in the past 60 years.
The global Dabigatran market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Dabigatran is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Dabigatran is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Dabigatran in Deep Vein Thrombosis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Dabigatran include Pfizer, Bayer Healthcare, GlaxoSmithKline, Boehringer Ingelheim, Aspen Holdings, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dabigatran, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dabigatran.
Report Scope
The Dabigatran market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dabigatran market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dabigatran companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bayer Healthcare
GlaxoSmithKline
Boehringer Ingelheim
Aspen Holdings
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries
Segment by Type
Tablets
Capsule
Others
Segment by Application
Deep Vein Thrombosis
Pulmonary Embolism
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dabigatran companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dabigatran Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tablets
1.2.3 Capsule
1.2.4 Others
1.3 Market by Application
1.3.1 Global Dabigatran Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Deep Vein Thrombosis
1.3.3 Pulmonary Embolism
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dabigatran Market Perspective (2019-2030)
2.2 Dabigatran Growth Trends by Region
2.2.1 Global Dabigatran Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Dabigatran Historic Market Size by Region (2019-2024)
2.2.3 Dabigatran Forecasted Market Size by Region (2025-2030)
2.3 Dabigatran Market Dynamics
2.3.1 Dabigatran Industry Trends
2.3.2 Dabigatran Market Drivers
2.3.3 Dabigatran Market Challenges
2.3.4 Dabigatran Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dabigatran Players by Revenue
3.1.1 Global Top Dabigatran Players by Revenue (2019-2024)
3.1.2 Global Dabigatran Revenue Market Share by Players (2019-2024)
3.2 Global Dabigatran Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dabigatran Revenue
3.4 Global Dabigatran Market Concentration Ratio
3.4.1 Global Dabigatran Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dabigatran Revenue in 2023
3.5 Dabigatran Key Players Head office and Area Served
3.6 Key Players Dabigatran Product Solution and Service
3.7 Date of Enter into Dabigatran Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Dabigatran Breakdown Data by Type
4.1 Global Dabigatran Historic Market Size by Type (2019-2024)
4.2 Global Dabigatran Forecasted Market Size by Type (2025-2030)
5 Dabigatran Breakdown Data by Application
5.1 Global Dabigatran Historic Market Size by Application (2019-2024)
5.2 Global Dabigatran Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Dabigatran Market Size (2019-2030)
6.2 North America Dabigatran Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Dabigatran Market Size by Country (2019-2024)
6.4 North America Dabigatran Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dabigatran Market Size (2019-2030)
7.2 Europe Dabigatran Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Dabigatran Market Size by Country (2019-2024)
7.4 Europe Dabigatran Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dabigatran Market Size (2019-2030)
8.2 Asia-Pacific Dabigatran Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Dabigatran Market Size by Region (2019-2024)
8.4 Asia-Pacific Dabigatran Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dabigatran Market Size (2019-2030)
9.2 Latin America Dabigatran Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Dabigatran Market Size by Country (2019-2024)
9.4 Latin America Dabigatran Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dabigatran Market Size (2019-2030)
10.2 Middle East & Africa Dabigatran Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Dabigatran Market Size by Country (2019-2024)
10.4 Middle East & Africa Dabigatran Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Dabigatran Introduction
11.1.4 Pfizer Revenue in Dabigatran Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Detail
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare Dabigatran Introduction
11.2.4 Bayer Healthcare Revenue in Dabigatran Business (2019-2024)
11.2.5 Bayer Healthcare Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Dabigatran Introduction
11.3.4 GlaxoSmithKline Revenue in Dabigatran Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Dabigatran Introduction
11.4.4 Boehringer Ingelheim Revenue in Dabigatran Business (2019-2024)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Aspen Holdings
11.5.1 Aspen Holdings Company Detail
11.5.2 Aspen Holdings Business Overview
11.5.3 Aspen Holdings Dabigatran Introduction
11.5.4 Aspen Holdings Revenue in Dabigatran Business (2019-2024)
11.5.5 Aspen Holdings Recent Development
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Detail
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company Dabigatran Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in Dabigatran Business (2019-2024)
11.6.5 Bristol-Myers Squibb Company Recent Development
11.7 Teva Pharmaceutical Industries
11.7.1 Teva Pharmaceutical Industries Company Detail
11.7.2 Teva Pharmaceutical Industries Business Overview
11.7.3 Teva Pharmaceutical Industries Dabigatran Introduction
11.7.4 Teva Pharmaceutical Industries Revenue in Dabigatran Business (2019-2024)
11.7.5 Teva Pharmaceutical Industries Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
